Tau is the major constituent of neurofibrillary tangles in Alzheimer's disease (AD), but the mechanism underlying tau-associated neural damage remains unclear. Here, we show that tau can directly interact with nucleoporins of the nuclear pore complex (NPC) and affect their structural and functional integrity. Pathological tau impairs nuclear import and export in tau-overexpressing transgenic mice and in human AD brain tissue. Furthermore, the nucleoporin Nup98 accumulates in the cell bodies of some tangle-bearing neurons and can facilitate tau aggregation in vitro. These data support the hypothesis that tau can directly interact with NPC components, leading to their mislocalization and consequent disruption of NPC function. This raises the possibility that NPC dysfunction contributes to tau-induced neurotoxicity in AD and tauopathies.
INTRODUCTION
The intracellular aggregation of tau in neurofibrillary tangles is a neuropathological hallmark of Alzheimer's disease (AD) (Ittner et al., 2010; Li et al., 2011; Thies and Mandelkow, 2007; Weingarten et al., 1975) . The progressive hyperphosphorylation and aggregation of tau in AD brains correlate well with synapse loss and neurodegeneration and thus may be a key driver of cognitive decline (Gó mez-Isla et al., 1996; Gong and Iqbal, 2008) . However, the mechanisms underlying tau aggregation and consequent cellular toxicity are unknown.
Nuclear pore complexes (NPCs) are responsible for the macromolecular trafficking of proteins and RNA between the nucleoplasm and the cytoplasm. They are molecular assemblies consisting of multiple copies of 30 different proteins called nucleoporins (Nups), eight of which contain intrinsically disordered domains rich in phenylalanine-glycine repeats (FG) (Denning et al., 2003; Labokha et al., 2013; Lemke, 2016; Milles and Lemke, 2011) . Nups are assembled in the NPC with specialized functional and spatial designations (Hinshaw et al., 1992) . FGcontaining Nups (FG-Nups) are attached to the nuclear scaffold via coiled-coil motifs in their non-FG domains (Dultz et al., 2008) . Their long unstructured polypeptide FG chains extend into the central channel, creating a hydrogel-like polymer brush that acts as a selectively permeable barrier for transport of proteins and other biomolecules (Floch et al., 2014; Frey et al., 2006; Lemke, 2016) .
Molecules smaller than $40 kDa can migrate freely through the NPC via passive transport (Timney et al., 2016; Wente and Rout, 2010) , whereas larger molecules require active transport mediated by interactions between nuclear transport receptors and Nups to pass through the central channel of the NPC (Frey and Gö rlich, 2007; Frey et al., 2006; Labokha et al., 2013; Petri et al., 2012) . During nuclear import, cargo is released into the nucleus when its transport receptor interacts with intranuclear RanGTP. Correspondingly, during nuclear export, cargo is released into the cytoplasm upon hydrolysis of RanGTP to generate RanGDP. As illustrated by this cycle, the nucleocytoplasmic gradient of RanGTP and RanGDP is essential for defining the directionality of nucleocytoplasmic transport (Dasso and Pu, 1998; Floch et al., 2014; Moore and Blobel, 1994) , and disruption of the Ran gradient can cause toxicity and cell death (Hetzer et al., 2002) . Nucleocytoplasmic transport has been shown to be disrupted in neurons in several neurodegenerative diseases, including C9orf72-mediated amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD) (Freibaum et al., 2015; Jovi ci c et al., 2015; Zhang et al., 2015) and Huntington's disease (Gasset-Rosa et al., 2017; Grima et al., 2017) , as well as in normal human aging (D'Angelo et al., 2009; Kelley et al., 2011; Lord et al., 2015; Mertens et al., 2015; Snow et al., 2013) . In the case of C9orf72-mediated ALS/FTD, intronic hexanucleotide repeats within C9orf72 produce RNA with expanded GGGGCC (G4C2) repeats that interact directly with RanGap1 (Zhang et al., 2015) , whereas in Huntington's disease, intranuclear huntingtin inclusions interact with both Nup62 and RanGap1 (Grima et al., 2017) . Changes in nuclear membrane morphology (Sheffield et al., 2006) , mislocalization of some transcription factors from the nucleus to the cytoplasm (Ke et al., 2012; Lu et al., 2014) , and Ran reduced expression have also been reported in postmortem tissues from AD cases (Mastroeni et al., 2013) , suggesting that analogous defects to those described in C9orf72-mediated ALS/FTD and Huntington's disease might occur in AD. However, the involvement of tau in these potential defects, as well as its more general role in nucleocytoplasmic transport, has not been studied.
Here, we show that phospho-tau-positive cells in human AD and tau transgenic mouse brains, as well as in cellular models of tau-related AD neuropathology, have an impaired nuclear transport. Indeed, we found that tau can interfere with NPC integrity in different ways. Tau directly interacts with the nucleoporin Nup98 in vitro, leads to cytoplasmic mislocalization of Nup98 in neurofibrillary tangles (NFTs) and in neurons with somatic phospho-tau in vivo, and induces a disruption of the NPC distribution in the nuclear membrane. Consequently, we observe failure of nuclear pore transport and diffusion-barrier properties, with changes in pore permeability to inert test molecules (dextrans) of various sizes, as well as alterations in active protein import and export, including Ran, an endogenous protein whose localization is known to be sensitive to NPC dysfunction. We further show that tau and Nup98 directly interact as assessed by co-immunoprecipitation from human AD brain tissue and surface plasmon resonance (SPR) of recombinant proteins. In addition, in vitro experiments show that Nup98 triggers tau aggregation and accelerates tau fibrilization and thereby possibly contributes to tau aggregation and tangle formation or stabilization in neuronal somata in AD and tauopathy brains.
In summary, we provide in vivo and in vitro evidence for a pathogenic model in which accumulation of tau in the somatodendritic compartment, as occurs in AD and tauopathies, increases the tau concentration in the perinuclear space and enables abnormal interaction of tau with Nups, which in turn leads to impairment in nucleocytoplasmic transport of biomolecules. These tau:Nup interactions may induce a pathological disruption of NPC function and contribute to tau-induced neurotoxicity. Targeting this pathway could provide a new therapeutic strategy for AD and similar neurodegenerative diseases.
RESULTS

Phospho-tau Leads to Abnormal Distribution of FG-Domain Nucleoporins in AD Brains
To test the hypothesis that tau interacts with components of the nuclear pore and leads to its functional impairment ( Figure 1A ), we first examined the distribution of tau and NPC components in postmortem hippocampal tissue from control and AD patients using immunofluorescence (Table S1 ). An abnormal, irregular distribution of NPCs in the nuclear membrane has previously been described for AD brain tissue (Sheffield et al., 2006) . Using a NPC marker, NPC [414] , that recognizes the FXFG repeats (FG domains) in several nucleoporins, including Nup62, but not Nup98, we found a homogeneous rim-like labeling of the nuclear membrane in human control brains ( Figure 1B) . In AD brains, the nuclear membrane NPC[414] staining was irregular and revealed a disturbed nuclear morphology with a crinkled appearance and invagination of the nuclear membrane and a strongly reduced membrane staining compared to controls ( Figure S1A ). Instead, FG-Nups ( Figure 1B ) and Nup62 ( Figure S1A ) occurred in the cytoplasm, suggesting a soma mislocalization. In hippocampal neurons without obvious NFTs, phospho-tau (detected with a mix [phospho-tau mix] of antibodies against phospho-tau epitopes pT181, pS199, pT205, pT231, and pS409) frequently colocalized with NPC[414] at the nuclear membrane ( Figure 1B) . Interestingly, the nucleoporin Nup133, which is an integral part of the NPC scaffold and lacks FG domains, showed neither cytoplasmic mislocalization nor a decrease in nuclear membrane staining in AD tissue ( Figure S1A ), suggesting that FG domains may be relevant for missorting of nucleopore components.
Cytoplasmic Phospho-tau Drives Nup98 into the Cytosol
The aberrant presence of FG-Nups in the neuronal cytosol of AD neurons led us to hypothesize that tau may interact with components of the NPC, presumably Nups with FG domains (FG-Nups), and induce their release from the nuclear membrane. To test this hypothesis, we focused on Nup98, which is one of the most abundant Nups and has the highest FG content (Schmidt and Gö rlich, 2015) . Nup98 is normally found on the cytoplasmic and nucleoplasmic edges of the NPC (Iwamoto et al., 2010; Powers et al., 1997) . In human control hippocampi, Nup98 was distributed evenly in the nuclear membrane of large neuronal nuclei (Figures 2A and S1B ), but smaller glia cell nuclei did not show strong Nup98 staining. The typically homogeneous distribution of Nup98 in the neuronal nuclear membrane was severely disrupted in AD brains and Nup98 mislocalized to the cytoplasm in neurons having somatic phospho-tau (phospho-tau mix, pT205, pT231, or PHF1; Figures 2A-2D ) or misfolded tau (Alz50; Figure S1C ). In some NFTs, a substantial amount of Nup98 appeared to be depleted from the nuclear membrane and present in the cytoplasm, often colocalizing with NFTs. Interestingly, another FG-Nup, Nup54, did not show overt missorting into the cytoplasm or depletion from the nuclear membrane in AD hippocampal neurons ( Figures 2E and S1D) . Additionally, the nuclear Nup Pom121 retained its normal localization in the nucleus. These data argued against a general disassembly of NPCs and release of their constituents in AD neurons with phospho-tau but rather suggested that the depletion from the nuclear envelope and the mislocalization into the cytosol was specific for a subset of Nups, including Nup98 and Nup62.
Free Nup98 Can Promote Tau Aggregation and Filament Assembly In Vitro
The C-terminal part of Nup98, which is normally located within the NPC scaffold and not accessible to proteins in the cytosol, is highly negatively charged ( Figure S2A ). Because tau aggregation is triggered by polyanionic macromolecules, for example, by heparin and RNA (Kampers et al., 1996 (Kampers et al., , 1999 Ramachandran and Udgaonkar, 2011) , we tested whether the presence of free polyanionic Nup98 C termini (Nup98-C; amino acids [aa] 645-911; Iso-electric point 4.99) could enhance tau aggregation and fibrilization in vitro. To assess the effect of Nup98 on tau aggregation, we incubated full-length 2N4R wild-type tau (WTtau) or mutant P301Ltau for several days in the presence of Nup-C and then assessed fibril formation by monitoring the fluores- Figure 1 . In AD, Tau Is Found at the Nuclear Membrane and NPCs Mislocalize to the Cytosol (A) Illustration describing how abnormal phosphotau that mislocalizes into the soma during AD interfaces with the cytoplasmic side of nuclear pore complexes. At the nuclear pore, pathogenic tau can disrupt nuclear pore complex function. (B) Human AD (Braak VI) and age-and sex-matched control brains were immunolabeled for phosphotau (green; p-tau mix of anti phospho-tau antibodies pT181, pS199, pT205, pT231, and pS409), NPCs (red; using mab414), and Dapi (blue). In AD cortex, phospho-tau accumulates in the cytosol and NPCs mislocalize from the nuclear membrane into the cytosol (arrowheads). In neurons with diffuse phospho-tau staining in the cytosol, phospho-tau also localizes to the nuclear membrane (arrows). Scale bar, 10 mm.
cence of the amyloid dye thioflavin S (ThioS) and by electron microscopy (EM) ( Figures 3A, S2B , and S2C). In the presence of heparin (0.04 mg/mL), recombinant C-terminal Nup98 (2 mM) significantly promoted tau (8 mM) fibril assembly (Figure S2B) . Even in the absence of heparin, a condition in which tau does not normally form fibrils, Nup98 strongly catalyzed tau fibrilization in a concentration and timedependent, heparin-independent manner ( Figures 3A, S2D , and S3). In the absence of heparin, neither Nup98 nor tau formed fibrils individually ( Figure S3 ). For these experiments, we kept the concentration of recombinant tau (tau-p0; WT or P301L) constant (10 mM or $0.4 mg/mL) and added Nup98-C at different molar ratios of Nup98-C:tau (1:27 [0. Figure 3A ), Nup98 promoted the aggregation of WTtau and P301Ltau, and at lower molar concentrations (Nup98:tau 1:8), Nup98 still effectively induced fibril assembly of P301L tau, but not WTtau. We also were interested in examining the interaction of full-length Nup98 with tau in the aggregation assays. However, although we were successful in the recombinant expression and purification of the C-and N-terminal half of Nup98 for the various assays (see also Figure 4 below), we were unable to purify the expressed full-length Nup98 properly and thus have been unable to gather an appropriate fulllength Nup98 for the aggregation and other assays.
To analyze whether both tau and Nup98 aggregate in this system or whether Nup98 only induces tau aggregation but stays soluble, we analyzed the insoluble (pellet after centrifugation at 90,000 3 g for 40 min at 4 C) and soluble (supernatant) fractions of the tau:Nup98 aggregation assays by western blot ( Figure 3B ). In samples with apparent tau aggregation (ThioS+ and fibrils in EM images), tau and Nup98 were found only in the insoluble fraction, whereby both aggregated Nup98 and tau appeared as high-molecular-weight (HMW) smear, indicating that Nup98 also had aggregated in these samples. Under similar conditions, immuno-EM with gold-particle-labeled tau (6 nm gold) and Nup98 (12 nm gold) suggested that Nup98 was integrated into the tau fibrils ( Figure S2E ). Furthermore, when we immunoprecipitated Nup98 from total AD brain lysate (Figures S2F and S2G) containing aggregated HMW tau, we found that both HMW tau and distinct monomeric full-length and truncated tau species interacted with Nup98. These data indicate that Nup98 can facilitate tau aggregation and also co-aggregates with tau in the cytosol, consistent with the observed tau-induced ''sequestration'' of Nup98 into the cytosol and the colocalization of Nup98 with intracellular phospho-tau in AD.
Phospho-tau Colocalizes with Nup98 and Nup62 at the Nuclear Membrane
To evaluate whether tau also interacts with nucleoporins anchored in intact NPCs in the nuclear membrane, we isolated nuclei from AD and control brain and performed high-resolution optical sectioning microscopy (Matevossian and Akbarian, 2008; Figures 4A and S4A) . 3D-rendered Z projections allowed the colocalization analysis of phospho-tau (phospho-tau mix) with Nup98 and Nup62 (NPC[414] ) in the nuclear membrane. Hippocampal nuclei from control brains showed a faint phospho-tau staining at their membrane, which only occasionally colocalized with NPCs ( Figures 4B and 4C ). In contrast, hippocampal nuclei from AD brains contained substantially more phospho-tau on the nuclear surface (Figures 4D), where phospho-tau colocalized with Nup98 ( Figure 4E ). We also found that the number of NPCs distributed in the nuclear membrane was significantly reduced in AD cases compared to controls ( Figure 4F ). In nuclei from visual cortex, a brain region having less pathologically hyperphosphorylated tau in AD, we still observed a small amount of phospho-tau associated with NPCs ( Figure S4B ), suggesting that low amounts of cytoplasmic phospho-tau may be sufficient to interact with NPCs. Taken together, these data suggest that, in disease conditions, cytoplasmic phospho-tau could directly interact with Nups in the nuclear membrane. (B) SDS-PAGE and western blot analysis of supernatants (soluble fractions) and pellets (insoluble fractions containing aggregated and polymerized tau and Nup98) from in vitro Nup98-tau aggregations. Membranes probed for tau (tau5) and Nup98 show that, for P301L tau, a tau:Nup98 ratio of 1:8 is sufficient to initiate tau aggregation. Monomeric and HMW species of tau and Nup98 are indicated. HMW tau and Nup98 species in the insoluble fractions indicate that one protein induces the other one to shift to higher molecular weight species, presumably through co-aggregation.
Phospho-tau Interacts Directly with the FG Domain of Nup98
Tau and Nup98 both have domains with similar high propensities for disorder as predicted by the DISPROT algorithm (Obradovic et al., 2003; Peng et al., 2005; Figure S2A) . Intrinsically disordered proteins (IDPs) have a propensity to interact with multiple binding partners through their ID domains (Lemke, 2016; Schmidt and Rohatgi, 2016; Wright and Dyson, 2015; Wu et al., 2017) . To determine whether tau, which is also intrinsically disordered, directly interacts with Nup98, we employed surface plasmon resonance (SPR) Wagner et al., 2015) . Recombinant phosphorylated human tau (tau-p12; in average 12 phosphorylated sites; produced in Sf9 insect cells; Tepper et al., 2014) or non-phosphorylated tau (tau-p0; produced in E. coli) was flowed in increasing concentrations over surface-tethered N-terminal FG domains of Nup98 (Nup98-FG; aa 1-498) and Nup62 (Nup62-FG; aa 1-240). An increase in binding response (RU) corresponded to increased tau:FG domain binding ( Figure S5A ). Phospho-tau appeared to directly interact with Nup98-FG ( Figure 4G ) and to a lesser degree with Nup62-FG ( Figure S5B ). Non-phosphorylated tau-p0 did not bind to Nup98-FG or Nup62-FG under these conditions, emphasizing the importance of phosphorylation or conformation of tau in its interaction with FG-Nups. The phosphorylation of tau-p12 has previously been shown to be similar to tau found in AD brains (Mair et al., 2016) . At low concentrations, phospho-tau bound to Nup98-FG and Nup62-FG but detached from the Nup layer upon reaching a critical concentration of $250 nM to $1 mM, accompanied by the return of the FG domain layer height to its initial value (Figures 4H and S5B) . This suggested that phospho-tau either aggregates or transitions to a higher order oligomerization state, which results in the detachment from the FG-Nup layer (Vovk et al., 2016) . We next tested whether the binding of tau-p12 was specific to the phenylalanine residues in Nup98 by using mutant Nup98 (Nup98-S), in which all phenylalanines have been replaced by serines. Interestingly, the lack of phenylalanines did not significantly reduce the tau-p12 interaction with Nup98-S ( Figures 4G and 4H) . However, the tau-p12 interaction appeared to be specific for the N-terminal FG domain of Nup98, and it did not interact with the highly negatively charged C-terminal domain of Nup98 ( Figure 4I) ; the C-terminal half of Nup98 is normally located within the NPC scaffold and not accessible ( Figure S2A ). Notably, tau-p12 did not interact with Nup133, a non-FG-Nup (and not cytoplasmically mislocalized (B and C) Images of nuclei extracted from control and AD hippocampal tissue after staining for phospho-tau (green) and either NPC (red; mab414 in B) or Nup98 (red in C). Displayed are maximum Z projections from the midline to the dorsal Z maximum of the nuclei. Note the accumulation of phospho-tau on the morphologically abnormal AD nuclei. Scale bar, 2 mm. (D-F) AD nuclei show higher levels of associate phospho-tau (D), colocalization of p-tau with NPC components (E), and a significantly reduced number of NPCs in the nuclear membrane (F). Graphs show quantification of punctae in 3D nuclei images using Imaris (see STAR Methods); n = 5 cases; n = 20 nuclei per sample. All graphs are presented as mean + SEM. *p < 0.5, **p < 0.01, and ***p < 0.001 by one-way ANOVA with Tukey's post-test. (G) Surface plasmon resonance (SPR) response curves show that recombinant human phospho-tau (tau-p12; 2N4R) binds to immobilized Nup98-FG and to Nup98-S. In contrast, non-phosphorylated tau (tau-p0) does not bind Nup98-FG and Nup98-S. n = 3 experiments. (H) Nup98 layers height changes corresponding to (G). n = 3 experiments; data presented as mean + SD. (I) SPR of tau-p12 and tau-p0 applied to C-terminal half of Nup98 (C-Nup98) reveals no significant binding. n = 3 experiments. (J) Tau protein was isolated from the HMW protein fraction (size exclusion chromatography) of AD brain homogenate using an anti-human tau affinity column (monoclonal antibody [mAb] HT7 recognizing human tau aa 159-163) containing phospho-tau (PHF-1) and Nup98. The identical sample was run simultaneously in parallel and western blotted for PHF1 and Nup98. in AD; Figure S1A ), in this assay, suggesting that the interaction between tau and Nup98 may to some extent be facilitated by the FG domains or other features of the N terminus of Nup98 ( Figure S5C) .
To test whether an interaction between phospho-tau and Nup98 also occurred in AD brain, we performed immunoaffinity purification (using HT7 anti-human tau antibody) of soluble tau isolated from a HMW fraction from a size exclusion column (Takeda et al., 2015) of homogenate from AD brains and probed it for the presence of Nup98 by western blot. Using this approach, we detected small amounts of Nup98 bound to HMW tau in AD brain ( Figure 4J ).
NPC Functional Loss: Phospho-tau Disrupts the NPC Diffusion Barrier in AD
In AD and tauopathies, the missorting of the otherwise mostly axonal microtubule-associated protein tau to the somato-dendritic compartment (Li et al., 2011; Thies and Mandelkow, 2007) enables its interactions with Nups in NPCs of the nuclear membrane. Our model suggests that this could induce the missorting of FG-Nups into the cytosol. We next tested whether the presence of phospho-tau in the somatodendritic compartment also leads to a functional impairment of nuclear pores. Uncompromised NPCs build a diffusion barrier across the nuclear membrane that excludes free passing of molecules larger than $40 kDa (Alber et al., 2007; Rabut et al., 2004; Timney et al., 2016; Weis, 2003) . The integrity of this NPC diffusion barrier can be evaluated using a nuclear dextran size exclusion assay (D'Angelo et al., 2009; Lé ná rt et al., 2003) , in which low-molecular-weight (25 kDa) dextran is expected to freely traverse NPCs and fill the nucleus, whereas higher molecular weight (e.g., 70-kDa and 500-kDa) dextrans should be excluded from the nucleoplasm when the NPCs are intact ( Figure S6A ). We tested the permeability of whole nuclei isolated from human brains at Braak (Braak and Braak, 1991) stages I (control), III (mild AD), and VI (severe AD) using fluorescent dextrans of different sizes (25-kDa, 70-kDa, and 500-kDa dextran) and compared their diffusion into the nuclei (Figures 5A and 5B ). Because it is smaller than the $40-kDa diffusion barrier threshold of intact NPCs, 25-kDa dextran filled the nucleus in control and AD brain nuclei ( Figure S6B ). However, hippocampal nuclei of Braak III and advanced Braak VI AD brains showed influx of the 70-kDa dextran and partial filling with 500-kDa dextran, demonstrating that these nuclei had a ''leaky'' NPC diffusion barrier ( Figure 5A ). Nuclei isolated from cerebellum, a brain region with minimal to no tau pathology even in advanced AD, excluded 70-kDa and 500-kDa dextran molecules, as did the vast majority of nuclei from control brains. These results suggest that NPC function becomes compromised in AD and that NPC dysfunction may accompany the progression of tau pathology. Note that the nuclear preparations included both neuronal and glial nuclei and, therefore, our analysis may underestimate the percent of leaky neurons.
Cytosolic Phospho-tau Disrupts the Nucleocytoplasmic Ran Distribution in AD Next, to assess the effect of tau on active nucleocytoplasmic transport of proteins, we examined the nuclear:cytoplasmic ratio of Ran protein, which can be used as an indicator of wellcontrolled transport of proteins and other biomolecules in and out of the nucleus (Dasso and Pu, 1998; Grima et al., 2017; Zhang et al., 2015) . To determine whether Ran is abnormally distributed in AD neurons with aberrant cytosolic tau, we immunofluorescently labeled Ran and phospho-tau (phospho-tau mix) in human AD and control hippocampal tissue ( Figure 5C ). In control hippocampal tissue, Ran showed a predominantly diffuse nuclear staining. In contrast, in AD brains, the nuclear Ran staining intensity was significantly diminished, presumably due to its mislocalization to the cytoplasm ( Figure 5D ). These Ran disruptions occurred predominately in phospho-tau-positive neurons.
To investigate whether soluble non-aggregated tau in the cytosol was contributing to the observed Ran disruptions in AD, we transfected cortical primary neurons with full-length WTtau (441 aa) or mutant P301Ltau, which is a pro-aggregating mutant of tau that is associated with familial frontotemporal dementia (FTDP-17; Figures S6C and S6D) . Interestingly, a similar decrease in nuclear:cytoplasmic Ran ratios was observed for both WTtau and P301Ltau, and we confirmed the presence of phospho-tau in these neurons by western blot of cell lysates (Figure S6E ). It appears that the presence of human phospho-tau in the cytosol is sufficient to initiate the Ran gradient deficits, even in absence of aggregation. This finding is in line with our SPR experiments, in which full-length tau-p12 binds to Nups. However, at this point, we cannot clearly distinguish whether high tau levels (due to tau overexpression) or the presence of phosphotau in the cytosol is driving the NPC functional impairment.
We then tested whether soluble tau could impact NPC function as well. We treated primary cultured murine neurons with a HMW protein fraction isolated by size exclusion chromatography (SEC) (Superdex 200 column) from human AD brain. This fraction contained soluble, oligomeric, highly phosphorylated tau that can be taken up by neurons in culture and then remains in the soma for days (Takeda et al., 2015) . Other tau-containing brain lysate SEC fractions from AD or control brains are not taken up by neurons (Takeda et al., 2015) . Remarkably, the addition of AD brainderived HMW protein caused rapid Ran mislocalization in primary neurons compared to untreated control neurons (Figures S6F and S6G) . These data suggest that soluble non-aggregated tau as well as even small amounts of soluble pathological tau in the cytoplasm might be sufficient to impact nucleocytoplasmic transport in neurons. Interestingly, neurons overexpressing the repeat domain fragment of tau, tauRD, did not show Ran impairments in absence of HMW AD protein ( Figure S6F ). These data indicated that a part of tau that is missing in tauRD (the N-terminal half or the C-terminal end) are involved in the binding and functional impact of tau on NPCs. The Ran deficit observed in neurons expressing tauRD and treated with HMW AD protein appears to be caused by the tau that was taken up.
Tau Impairs Active Nuclear Import and Export in Neurons To explore the effect of tau on nuclear pore function in more detail, we developed assays to monitor active nuclear import and export of fluorescent reporter proteins in neurons. First, we expressed the fluorescent nuclear import reporter nuclear localization signal (NLS):tdTomato:nuclear export signal (NES) (Zhang et al., 2015) in neurons and then treated them with the Alexa Fluor 647-labeled HMW AD protein fraction for 24 hr, 48 hr, or 72 hr. In healthy neurons, active nuclear import causes the NLS-tagged tdTomato to rapidly shuttle into the nucleus (Figure 6A) , which leads to a complete fluorescence recovery after photobleaching (FRAP) of tdTomato in the nucleus. However, we found that neurons that had taken up tau into the cell body showed significantly reduced FRAP compared to untreated neurons (Figures 6A and 6B ; $50% decrease) after 24 hr. However, no further decrease in the FRAP was observed after 48 hr and 72 hr, suggesting that tau-mediated nuclear import impairments occurred in the first 24 hr after the uptake of tau and persisted for at least 2 days.
We then tested whether nuclear protein export was also impacted by tau. Expressing the construct 23GFP:NES-IRES-23RFP:NLS in neurons leads to the stoichiometric production of 23RFP:NLS in the nucleus and 23GFP:NES in the cytosol  Figure 6C ). In neurons treated with ADbrain-derived HMW protein, we detected red fluorescent protein (RFP) and GFP in the nucleus after 24 hr ( Figure 6D ), indicating rapid defects in nuclear protein export. Furthermore, RFP was detected in the cytosol after 48 hr, consistent with nuclear protein import defects. These data revealed that uptake of HMW tau from AD brain was sufficient to functionally impair both the protein import and export functions of the NPC.
Tau Aggregation Causes NPC Impairment in Tau Transgenic Mice
To extend these observations in vivo, we next evaluated the nuclear integrity in two tau-overexpressing mouse lines. We analyzed the brains of human wild-type tau-expressing mice (rTg21221; Hoover et al., 2010; Jackson et al., 2016 ) that have increased tau phosphorylation but no tangle formation or neuronal loss, even at advanced age, and compared them to mice expressing human FTD mutant P301Ltau at similar levels (rTg4510; Santacruz et al., 2005) , which develop extensive tau neurofibrillary tangle pathology and severe neuronal loss in the hippocampus and cortex starting at $9 months.
Using the dextran permeability assay, we found that nuclei isolated from 14-month-old wild-type and rTg21221 mice excluded both 70-kDa and 500-kDa dextran dyes, whereas nuclei from age-matched rTg4510 mice showed influx of the 70-kDa dextran and partially of the 500-kDa dextran, demonstrating nuclear leakage of rTg4510 nuclei similar to hippocampal AD nuclei (Figures S7A and 5A for human nuclei).
Furthermore, in immunolabeled brain sections, rTg4510 (14-month-old) neurons with aggregated phospho-tau in the soma showed Ran depletion from the nucleus; Ran occasionally colocalized with tau in the soma (Figures 7A and 7B ). rTg21221 mice showed neuronal Ran alterations only in a few neurons, suggesting that nuclear Ran depletion in vivo is not merely linked to the overexpression of human tau but is specific to the presence of misfolded or aggregated tau in the soma. To test the possibility that the observed nuclear Ran depletion is non-specifically associated with neurodegeneration, we also analyzed transgenic mice that express human APP and develop robust Ab-plaque pathology and gliosis in hippocampus and cortex (APP/PS1; Radde et al., 2006) . APP/PS1 mice showed no alterations in nuclear Ran in hippocampal neurons ( Figures 7A and 7B) .
Interestingly, the observed Ran alterations in rTg4510 mice appeared to correlate with the mislocalization of Nups into the cytoplasm in these mice. In brain sections from the same mice immunolabeled for Nup98 (anti-N-terminal Nup98) and phospho-tau, only rTg4510 mice had cytoplasmic Nup98 accumulations and severe irregularities in the nuclear shape, characterized by loss of circularity and nuclear membrane folds ( Figure S7B ). We were also able to confirm the presence of Nup98 in the cytosol of hippocampal rTg4510 neurons using a C-terminalspecific Nup98 antibody, indicating that full-length Nup98 protein-and not only the FG-domain-harboring N-terminal halfwas present in the cytosol and in tau aggregates ( Figure S7C ).
Soluble Phospho-tau Reduction Can Restore NPC Impairment in Mice Because Nup98 mislocalization to the cytoplasm and colocalization with tau occurred in rTg4510 mice, but not in wild-type mice, we reasoned this effect could be due to an interaction of Nup98 with fibrillar tau and/or with a soluble tau present in the soma. We tested whether the removal of soluble human P301Ltau and attenuation of tau aggregation in rTg4510 mice could prevent Nup98 mislocalization and Ran gradient deficits in these mice. In both rTg4510 and rTg2122 mice, the expression of the human tau transgene can be suppress by doxycycline (DOX) (DeVos et al., 2018; Santacruz et al., 2005) . 6-month-old rTg4510 mice, which had pronounced phosphotau but minor hippocampal tangle pathology, were treated with DOX (food) for 6 months, so that soluble tau was rapidly removed, and relatively few tangles were still present after 6 months of treatment (Santacruz et al., 2005) . At 12 months of age, untreated rTg4510 mice showed severe cytoplasmic Ran mislocalization ($25% nuclear Ran intensity compared to WT; Figures 8A and 8B) . Strikingly, DOX treatment rescued the nuclear localization of Ran back to control levels, and Nup98 reappeared in the nuclear membrane, even in the neurons that still contained tangles. Moreover, although Nup98 reappeared in the nuclear membrane after tau suppression, it was still possible to detect Nup98 in neurofibrillary tangles (Figures 8A and 8C) , suggesting that this may be a long-lived stable complex. These findings suggest that soluble misfolding phospho-tau was mainly responsible for Nup98 displacement from NPCs and nucleocytoplasmic transport deficits observed in rTg4510 mice.
Reduction of Nup98 Decreases NPC Defects in Neurons
We showed that mislocalized Nup98 accumulations in the perinuclear space co-occur with tau pathology in AD. To determine whether Nup98 is directly contributing to tau-induced nucleocytoplasmic transport disruption and Ran mislocalization in a disease-relevant model, we tested whether the knockdown of Nup98 via lenti-viral short hairpin RNA (shRNA) can affect the Ran nuclear:cytoplasmic ratio in primary neurons from human tau P301Stau-expressing transgenic mice (PS19 line; Figure S8 ). Prior to Nup98 knockdown with shRNA, the neurons were treated with the soluble fraction of total brain homogenates from control or AD brains to enhance the amount of aggregated tau in the soma. In neurons that received AD lysate, the nuclear: cytoplasmic Ran ratio was significantly reduced by $50% (Figures S8A and S8C) . Surprisingly, anti-Nup98 shRNA treatment (which reduced Nup98 by $70%; Figure S8B ) of neurons with AD lysate rescued the Ran ratio reduction almost completely to a level observed in neurons treated with control lysate (Figure S8C) . This indicated that a reduction of Nup98 could possibly prevent AD tau-induced disruption of the Ran gradient in primary neurons.
DISCUSSION
Substantial evidence suggests that alterations in nucleocytoplasmic transport contribute to familial forms of several neurodegenerative diseases (Basel-Vanagaite et al., 2006; Gasset-Rosa et al., 2017; Grima et al., 2017; Kaneb et al., 2015; Zhang et al., 2015) . Furthermore, in vitro and in vivo models of these diseases are consistent with age-related deterioration of NPCs and the loss of nuclear integrity (D'Angelo et al., 2009; Kelley et al., Comparing hippocampal (CA1) brain sections from agematched WT and rTg4510 mice with or without DOX treatment from 6 to 12 months of age, we found that Ran (pink) was depleted from most neuronal nuclei (white outlined) in rTg4510. Ran was present in the nucleus in DOX-treated rTg4510, even in presence of remaining aggregated phospho-tau (green) in the soma. Nup98 (red) mislocalized to the somata in rTg4510 and rTg4510+DOX neurons with cytosolic phospho-tau (green). Scale bars in merged images, 40 mm; scale bars in zoomed images, 10 mm. (B) Quantification shows that the nuclear Ran intensity was fully restored in DOX-treated animals, which have decreased soluble phospho-tau. n = 3 per group; 100 nuclei per group. Data are presented as mean + SEM. **p < 0.01, ***p < 0.001, and ****p < 0.0001 by one-way ANOVA with Tukey's post-test. (C) The colocalization of Nup98 with phospho-tau significantly decreased in DOX-treated animals. n = 3 per group. Data are presented as mean + SEM. **p < 0.01, ***p < 0.001, and ****p < 0.0001 by one-way ANOVA with Tukey's post-test.
2011; Lord et al., 2015; Mertens et al., 2015; Snow et al., 2013) . In AD, observations of irregularities in nuclear morphology have suggested a contribution of nuclear dysfunction to pathophysiology (Sheffield et al., 2006) , although the underlying mechanism has remained unexplored. A pathophysiological role of tau in and at the nucleus has been suggested (Ferná ndez-Nogales et al., 2014; Loomis et al., 1990; Sultan et al., 2011; Violet et al., 2014) , although it has remained unknown whether nucleocytoplasmic transport defects are linked to tau pathology in AD.
Our study provides multiple lines of evidence that pathological tau directly interacts with components of the NPC that can accelerate aggregation and fibrilization of tau in the cytoplasm and disrupts NPC structure and function. We demonstrate that full-length tau can interact with Nup98 and to a lesser extent with other FG-Nups, such as Nup62, in postmortem AD cases, in transgenic mouse models, and in vitro. We also show evidence of NPC structural defects, including Nup98 pathology, and functional impairments, including Ran mislocalization; alterations in fluorescent protein trafficking; and defects in dextran exclusion, in phospho-tau-positive cells from AD patients, rTg4510 transgenic mice, and primary neurons. Because neurons that take up exogenous AD brain-derived tau have altered nuclear cytoplasmic Ran distribution, our study suggests that the presence of pathophysiological tau directly disturbs NPC function and integrity, consequently altering both nuclear protein export and import. In cells transfected with full-length wild-type or P301L tau, soluble tau also caused disruption in the Ran gradient. Soluble tau appeared to be sufficient to cause this phenotype, as introduction of soluble tau derived from AD cortex caused NPC alterations and tau transgenic mice treated with DOX to suppress expression of soluble tau were efficiently rescued from tau-induced Ran and Nup98 alterations despite the continued presence of neurofibrillary tangles. The neurons with neurofibrillary tangles remaining after DOX treatment appeared to have Ran restored to the nucleus and Nup98 incorporated into the nuclear membrane, although a portion of Nup98 remained localized to neurofibrillary tangles. Tau and Nup98 co-immunoprecipitated in a complex from concentrated human AD brain fractions, and tau interacted in a phosphorylation-dependent manner with the N-terminal FG domain of Nup98 and to a lesser extent with FG domains of Nup62. Additionally, using an in vitro tau fibrilization assay, we observed that the negatively charged Nup98 C-terminal domain strongly enhanced tau fibril formation in a heparin-independent manner. The catalytic role of C-terminal Nup98 on tau fibril assembly was independent of tau phosphorylation and was more effective with P301L tau. These results are consistent with a model in which neuronal conditions that bring tau in close proximity to the perinuclear space, such as hyperphosphorylation and missorting of tau in AD, would enable tau interaction with FG-Nups and therefore trigger NPC malfunction.
Although the consequences of morphological alterations in the NPC have not been studied directly in AD, several previous studies support our data. For example, multiple transcription factors, including the aging-related protective RE1-silencing transcription factor (REST), become mislocalized from the nucleus to the cytoplasm in AD, FTD, and Lewy body dementia (Lu et al., 2014) . TDP-43, which is also involved in transcription and splicing, mislocalizes to the cytoplasm and aggregates in the neuronal cytosol in ALS, FTD, and AD (Amador-Ortiz et al., 2007; Freeman et al., 2008; Winton et al., 2008) . Interestingly, the splicing factor proline and glutamine-rich (SFPQ), which regulates MAPT exon 10 splicing in the nucleus, accumulates in the cytoplasm in the presence of pathological phospho-tau in AD and FTD (Ishigaki et al., 2017; Ke et al., 2012) . We previously demonstrated that the mislocalization of TDP-43 in C9orf72-mediated ALS/FTD may be a consequence of defective nuclear import (Zhang et al., 2015) . The current study suggests that the mislocalization of these proteins in human AD and tauopathy transgenic mouse model may be a consequence of tau-mediated nucleocytoplasmic transport disruption.
Given that Nup98 is responsible for the guanosine diphosphate (GDP)/guanosine triphosphate (GTP) exchange of Ran as well as the termination of nuclear import (Fontoura et al., 2000) , Nup98 disruption could precipitate abnormal Ran distribution. Additionally, as Nup98 is directly involved in mRNA export (Blevins et al., 2003) , the sequestration of Nup98 may also further link tau aggregation to the growing evidence that several RNA-binding proteins may contribute to tau pathology observed in AD and other tauopathies (Maziuk et al., 2017; Vanderweyde et al., 2016) . Indeed, tau aggregation and stress granule formation are closely connected (Vanderweyde et al., 2016) . Notably, we recently provided evidence of concomitant dysregulation of stress granule dynamics and nucleocytoplasmic transport . Future studies unraveling the interplay between tau-induced NPC malfunction and altered stress granule dynamics in tauopathies (Vanderweyde et al., 2016 ) may lead to a better understanding of the etiology of nuclear transport defects in AD and other tauopathies.
Data from SPR experiments demonstrate that the FG domains of Nup98 and Nup62 do not interact with non-phosphorylated tau. In contrast, a phosphorylated version of tau, tau-p12, can readily bind and accumulate within FG domain layers formed by either of these proteins. The interaction between Nup98 and tau-p12 is facilitated by the disordered N-terminal FG domains of Nup98, although the exact nature of their interaction remains unclear. Indeed, replacing phenylalanine (Nup98-F) with serine (Nup98-S) did not abrogate their interaction. It is plausible that tau-p12 binds the FG domains in a manner that differs from that of nuclear transport receptors (e.g., importin-beta; Kapinos et al., 2014) to promote aggregation at the NPC. Earlier studies showed that in vitro assemblies of the N-terminal Nup98 FG domain can self-assemble into a polymer brush-like layer that exhibits a selectivity similar to intact NPCs (Kowalczyk et al., 2011; Schmidt and Gö rlich, 2015; Ando et al., 2014; Osmanovi c et al., 2013) . Because phospho-tau (which also can form a polyelectrolyte brush; Wegmann et al., 2013) in the cytosolic vicinity of the nuclear membrane affects the selectivity of the NPC, it is possible that the interaction of tau with the polymer brush formed by Nup98 (and other FG-Nups) impairs its selective transport barrier properties. We speculate that cytosolic phospho-tau might impair cellular NPCs by crosslinking and inducing aggregation of the pore's FG-Nups. We note that the Nup98 C-terminal domain can promote tau fibrilization and that the N-terminal FG domain of Nup98 physically interacts with phospho-tau. This finding may suggest a model in which the N terminus of Nup98 directly interacts with tau, providing an anchor in which the highly negatively charged C-terminal domain of Nup98 can catalyze even more fibril formation. The N-terminal domain physically tethers the two proteins, allowing the negatively charged C-terminal to neutralize the lysines in tau in a manner similar to heparin (Ramachandran and Udgaonkar, 2011) .
Deposits of cytoplasmic protein aggregates may interfere with nuclear import and export and can lead to neuronal death (Woerner et al., 2016) . The impairment of nucleocytoplasmic transport in response to stress-granule-induced cytoplasmic aggregates as well as aberrant cytosolic tau accumulation highlights a potentially common toxic mechanism in protein aggregation diseases, in which protein aggregates disrupt the integrity of NPCs, impair neuronal nucleocytoplasmic transport, and ultimately lead to neurodegeneration. Similar phenomenon has been observed in TDP-43 ALS/FTD models, where mislocalized cytoplasmic aggregates of TDP-43 were found enriched for NPC components and nucleocytoplasmic transport. The aggregated protein sequestered and mislocalized nucleoporins and transport factors, which impaired the nuclear import and RNA export in neurons (Chou et al., 2018) .
Taken together, our data provide an unconventional mechanism for tau-induced neurodegeneration. Our studies indicate that tau-induced impairments of nucleocytoplasmic transport can occur upon accumulation of soluble phospho-tau in the neuronal soma or by mutant tau misfolding in AD and FTD, possibly even without overt tau aggregation in neurofibrillary tangles. Our study provides new biological understanding of tau fibril formation and also pathophysiological mechanisms that could be targeted for potential therapeutic interventions. These data suggest that strategies that reduce tau or prevent tau interactions with Nup98 could not only restore nucleocytoplasmic transport but also decrease tau aggregation and may therefore be promising therapeutic approaches for AD, FTD, and other neurodegenerative diseases.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Ethics statement All animal care, housing, and experiments were performed in compliance with guidelines established by the Center for comparative medicine (CCM) at Massachusetts General Hospital (MGH) and in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Wild-type, rTg4510, rTg21221, APPPS1 mice tissues were and prepared for immunostaining at MGH.
Autopsy tissue from Control, AD and FTD cases from both Johns Hopkins and MGH were collected with informed consent of patients or their relatives and approval of local institutional review boards. Human patient demographic information for control and AD is provided in Table S1 .
AD and control human cases All control and AD human brain samples used in this study are from age-and sex-matched individuals that were classified into Braak stages (I-VI) based on their pathological tau accumulation. Given that tau accumulation can be observed in the normal aging process, we used Braak I cases without cognitive impairments as controls. Additionally, each patient was pathologically characterized based on their Thal phase for Abeta plaques, and CERAD neuritic plaque score, as previously described (https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC3268003/).
AD and FTD mouse models
For all experiments, mice from both genders were used, group housed in standard cages under a 12 hr light/dark cycle with ad libitum access to water and food. Center for comparative medicine (CCM) in Mass General Hospital (MGH) was the centralized provider of veterinary medical care and research animal support. RAR ensured that mice are regularly checked for standard pathogens and health status. Health reports can be provided upon request. All mice had a standard specific-pathogen-free (SPF) and immune status.
rTg4510, rTg21221 and APPPS1 mice rTg4510, rTg21221, and APP/PS1 transgenic mice and their control littermates were obtained from breeding colonies maintained at McLaughlin Research Institute in Montana. All offspring were genotyped using tail DNA. rTg4510 mice overexpress human mutant P301Ltau (0N4R) under the CamK2a promotor, which leads to a a brain-wide overexpression ($10-fold) of P301Ltau in excitatory neurons and pronounced tau phosphorylation and NFT formation in the hippocampus and cortex from the age of $9 months. The tau transgene is inserted in a Tet-repressible operon so that doxycycline treatment (food) dramatically reduces the expression of tau in the forebrain of these animals (Santacruz et al., 2005) . rTg21221 mice express human wild-type tau (0N4R) under the same promotors and at similar levels as rTg4510s, and also under a Tet-repressible operon (Hoover et al., 2010) . These mice develop tau hyperphosphorylation but no tau aggregation from $12 months of age. APP/PS1 mice contain transgenes for human APP and bearing the ''Swedish'' mutation (K595N/M596L) and for PSEN1 containing the L166P mutation, both under the control of the Thy1 promoter. In these mice, expression of the human APP transgene is approximately 3-fold higher than endogenous murine APP (Radde et al., 2006) . APP/PS1 mice develop amyloid-plaques in the cortex and hippocampus from $6 months. Non-transgenic littermates were used as controls for APP/PS1 mice, and Tet-operon positive but tau transgene negative mice were used as controls for rTg4510 and rTg21221 mice.
14-month old transgenic mice and their control littermates were used for immunofluorescence studies of Ran and Nup98. 6-month old rTg4510 mice were used for the Dox treatment study and were treated (chow containing 200 mg/kg doxycycline (Harlan Teklad, South Easton, MA) for 6 months and then were used for the immunofluorescence studies. To harvest the brains, all mice were anesthetized and transcardially perfused with phosphate-buffered saline (PBS). The left half of the brains were post-fixed for R 48 hr in 4%-paraformaldehyde (Electron Microscopy Services) in PBS, followed by cryoprotection in 30% (w/v) sucrose/PBS for 2-3 days at 4 C. Coronal brain sections (40 mm) were cut on a freezing microtome and used for immunofluorescence.
METHOD DETAILS
Primary neuron cultures and transfection Primary cortical mouse neurons were prepared from cerebral cortices of wild-type CD1 or P301Stau transgenic PS19 mouse embryos (E14-15, Charles River Laboratories) using a papain dissociation system (Worthington Biochemical Corporation) as described previously (Takeda et al., 2015) . Briefly, cortices were dissected out and mechanically dissociated in Neurobasal medium (Thermo Fisher) supplemented with B27, 2 mM Glutamax, 100 U/mL penicillin and 100 g/mL streptomycin, and plated in the same medium at a density of 0.6*10 5 cells per well of a poly-D-lysine (50 mg/mL 1, Sigma) treated Nunc Lab-Tek II Chambered Coverglass or on 35 mm dishes (Corning). Cultures were maintained at 37 C with 5% CO 2 in Neurobasal medium with 2% (v/v) B27 nutrient, 2 mM Glutamax, and antibiotics as above. On day 7, neurons were transfected with 2.5 mg per 6-well of DNA for 3.5 hr using Lipofectamine 2000 following manufacturer instruction. All the experiments were done 48 hr after transfection.
